Poly-ADP-ribose polymerase (PARP) inhibitors and ovarian function

Biomed Pharmacother. 2023 Jan;157:114028. doi: 10.1016/j.biopha.2022.114028. Epub 2022 Nov 18.

Abstract

Poly-ADP-ribose polymerase (PARP) plays an important role in DNA damage detection and repair. PARP inhibitors (PARPi) are a novel class of targeted agents used widely in the treatment of female cancer patients with BRCA mutations, including younger patients. However, the impact of PARPi on ovarian function remains a considerable problem in clinical practice. In this review article, we summarize the current understanding of PARPi's effects on the function of ovary and discuss their potential underlying mechanisms, highlighting the significance of further investigation on the criterion for ovarian failure and its preventive approaches during PARPi treatment.

Keywords: BRCA mutation; DNA repair; Fertility; Ovarian function; PARP inhibitor.

Publication types

  • Review

MeSH terms

  • Adenosine Diphosphate Ribose / therapeutic use
  • DNA Damage
  • Female
  • Humans
  • Ovarian Neoplasms* / drug therapy
  • Ovarian Neoplasms* / genetics
  • Poly(ADP-ribose) Polymerase Inhibitors / pharmacology
  • Poly(ADP-ribose) Polymerase Inhibitors / therapeutic use
  • Poly(ADP-ribose) Polymerases* / genetics

Substances

  • Poly(ADP-ribose) Polymerases
  • Poly(ADP-ribose) Polymerase Inhibitors
  • Adenosine Diphosphate Ribose